ASH 2018 | Ruxolitinib plus azacitidine for myelofibrosis

Naval Daver

Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, presents the results of a Phase II study of ruxolitinib in combination with azacitidine in patients with myelofibrosis (NCT01787487), which were reported at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video